HECA Inhibitors
Chemical inhibitors of HECA protein operate through various molecular pathways to modulate the activity of this protein. Staurosporine and Go6983, both protein kinase C inhibitors, can disrupt downstream signaling that involves HECA protein. By blocking protein kinase C, they reduce phosphorylation of targets that are presumably necessary for HECA protein's regulatory functions. Similarly, LY294002 and Wortmannin target phosphoinositide 3-kinase, resulting in the blockade of activation signals crucial for HECA protein's roles in cellular processes such as migration and adhesion. These inhibitors collectively act by impeding the phosphorylation cascade that would normally involve the HECA protein, thus inhibiting its activity.
Further along these lines, PD98059 and U0126, as inhibitors of MEK, suppress the MAPK/ERK signaling pathway, a route thought to be significant for HECA protein's involvement in organizing the actin cytoskeleton. SB203580's selective inhibition of p38 MAP kinase and SP600125's inhibition of c-Jun N-terminal kinase interfere with stress responses and transcriptional regulation, respectively, which are processes potentially regulated by HECA protein. Inhibition of these kinases can therefore reduce HECA protein's influence on these cellular responses. NF449, by selectively inhibiting the Gs-alpha subunit of G proteins, disrupts G protein-coupled receptor signaling that HECA protein may depend on. ML7, through its inhibition of myosin light chain kinase, can diminish HECA protein's role in cellular motility. Additionally, BAPTA-AM, by chelating intracellular calcium, can affect calcium-mediated activation of HECA protein, leading to a reduction in its activity in signaling pathways where calcium is a key secondary messenger. Collectively, these inhibitors provide a multifaceted approach to modulating HECA protein's activity within cells by targeting various signaling mechanisms and kinases that contribute to its function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinase C, which is involved in the signaling pathways that HECA protein may regulate. Inhibition of protein kinase C leads to decreased phosphorylation of downstream targets, potentially reducing HECA protein activity that relies on such phosphorylation events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it prevents the activation of downstream signals that may be required for the function of HECA protein in cellular migration and adhesion processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is part of the MAPK/ERK pathway. HECA protein is implicated in cell signaling related to actin cytoskeleton organization; inhibition of MEK could reduce ERK pathway activity, thereby diminishing the functional role of HECA protein in this context. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that, similar to PD98059, can suppress the MAPK/ERK signaling pathway. The inhibition of this pathway can lead to reduced activity of HECA protein if it is involved in ERK-mediated cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. Since p38 MAP kinase is involved in stress responses, its inhibition can disrupt pathways where HECA protein might play a regulatory role, thereby inhibiting HECA protein function indirectly. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which can affect transcription factors and cellular responses that HECA protein might influence. Inhibition of JNK can therefore inhibit the functional activity of HECA protein related to these responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K like LY294002. By inhibiting PI3K, it blocks the pathways necessary for certain aspects of HECA protein function, particularly those related to cell survival and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in cell growth and proliferation. Since HECA protein is implicated in cell signaling, the inhibition of mTOR may lead to a decrease in HECA protein's functional roles in these processes. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gs-alpha subunit of G proteins. By inhibiting this subunit, it can disrupt G protein-coupled receptor signaling, potentially inhibiting HECA protein activity that is GPCR dependent. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a calcium chelator that can reduce intracellular calcium levels. Given that calcium signaling may be involved in the functional activation of HECA protein, the reduction of calcium levels can inhibit HECA protein activity. | ||||||